Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?
Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would? About the Author Reprints By Kate Sheridan Feb. 13, 2019 Reprints General Assignment Reporter Kate covers biotech startups and the venture capital firms that back them. Something Ventured [email protected] Log In | Learn More What’s included? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here. Biotech is an industry defined by splashy startups pitching groundbreaking, life-changing treatments — if only they had a bit more money to test them. But unless those companies eventually go public, finding out exactly what’s going on behind the scenes can be tricky. For outsiders, sporadic press releases may contain the only clues, even as companies continue to pull in venture funding or other investments. GET STARTED Kate Sheridan What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Hyacinth Empinado/STAT @sheridan_kate Tags biotechnologyBostoncancerdrug developmentresearchstartupSTAT+